Mexico conference considers pre-exposure prophylaxis for AIDSBMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a1278 (Published 14 August 2008) Cite this as: BMJ 2008;337:a1278
- Bob Roehr
The possible use of a daily pre-exposure prophylactic pill against AIDS raised interest at last week’s 17th international AIDS conference because of the recent failures of trials of vaccines and microbicides.
Several studies of pre-exposure prophylaxis are being launched in different parts of the world. Most involve a combination of two popular anti-HIV drugs, tenofovir and emtricitabine, in one pill, marketed as Truvada. The combination has amassed millions of people years of use. It seems to be safe, well tolerated, and holds the virus in check.
There are biological reasons to think that pre-exposure prophylaxis can work, and trials in monkeys are …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial